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ABSTRACT We analysed a cohort of patients with normotensive pulmonary embolism (PE) in order to
assess whether combining echocardiography and biomarkers with the pulmonary embolism severity index
(PESI) improves the risk stratification in comparison to the PESI alone.
The PESI was calculated in normotensive patients with PE who also underwent echocardiography and
assays of cardiac troponin I and brain natriuretic peptide. 30-day adverse outcome was defined as death,
recurrent PE or shock.
529 patients were included, 25 (4.7%, 95% CI 3.2–6.9%) had at least one outcome event. The proportion
of patients with adverse events increased from 2.1% in PESI class I–II to 8.4% in PESI class III–IV, and to
14.3% in PESI class V (p,0.001). In PESI class I–II, the rate of outcome events was significantly higher in
patients with abnormal values of biomarkers or right ventricular dilatation. In multivariate analysis, the
PESI (class III–IV versus I–II, OR 3.1, 95% CI 1.2–8.3; class V versus I–II, OR 5.5, 95% CI 1.5–25.5 and
echocardiography (right ventricular/left ventricular ratio, OR (for an increase of 0.1) 1.3, 95% CI 1.1–1.5)
were independent predictors of an adverse outcome.
In patients with normotensive PE, biomarkers and echocardiography provided additional prognostic
information to the PESI.
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Introduction
Early mortality from pulmonary embolism (PE) depends on the clinical consequences of PE and on the
underlying disease [1]. Risk stratification of patients with PE may enable definition of a low-risk group that
may be treated on an outpatient basis and a high-risk group that should be admitted to hospital for close
medical supervision [2]. The pulmonary embolism severity index (PESI), a clinical rule based on 11 clinical
variables, defines five classes of patients with PE with different mortality rates at 90 days [3]. The PESI has
been validated in several large cohorts and is now available as a simplified version based on seven variables
[4–6]. Right ventricular dysfunction, assessed by either echocardiography or spiral computed tomography,
and high levels of biomarkers, including cardiac troponin I (cTnI) and brain natriuretic peptide (BNP),
have been linked to an increased risk of death or adverse outcome in patients with PE [7–9]. Little is known
about the respective roles of the clinical findings summarised in the PESI, echocardiography and biomarkers
for the risk assessment of patients with PE. We analysed the results of a large prospective multicentre cohort
of consecutive patients with PE in order to determine whether the combination of echocardiography and
biomarkers with the PESI improves the risk stratification of patients with PE compared with the PESI alone
[8]. Cardiogenic shock at admission represents one of the most important prognostic factors in patients
with PE and, according to the current guidelines of the European Society of Cardiology, it is widely
admitted that further risk stratification by biomarkers, echocardiography or the PESI is not needed in these
patients [2]. Therefore, we focused our study on patients with normotensive PE.
Material and methods
Patients
Consecutive adult patients with symptomatic normotensive PE admitted in the 11 participating sites in
France, Belgium and Switzerland were recruited for the study. Patients were eligible if their PE was
objectively confirmed according to current guidelines, as previously reported [2, 8]. Patients were ineligible
for the study if they had received therapeutic doses of anticoagulant treatment for .24 h or had cardiogenic
shock at admission defined by at least one of the following criteria: systolic blood pressure ,90 mmHg,
signs of end-organ hypoperfusion or a need for catecholamine administration to maintain systolic blood
pressure .90 mmHg. Because the role of thrombolytic therapy remains unclear in clinically stable patients,
we excluded patients with normotensive PE who received fibrinolytic treatment. Demographic data,
symptoms and risk factors for venous thromboembolism, including all variables of the PESI, were obtained
at the time of admission. Patients were managed according to the usual practices of each participating site
by physicians blinded to the results of cardiac biomarkers.
The study protocol strongly recommended transthoracic echocardiography within 24 h of PE diagnosis by
an experienced physician unaware of the results of cardiac biomarker determinations. The end-diastolic
diameters of the right and left ventricles were measured along the long axis of the parasternal view and the
right ventricle/left ventricle ratio was calculated [8].
On admission, blood samples were collected in heparinised tubes for the cTnI assay and in EDTA tubes for
BNP determination, tubes were centrifuged and the resulting plasma was frozen and stored at -80uC. At the
end of the study, circulating levels of cTnI and BNP were determined in a central laboratory by investigators
blind to the patients’ baseline characteristics and clinical outcome. cTnI levels were determined with
quantitative photometric immunoassays using a Dimension-RxL Max analyser (Dade-Behring, Siemens
Healthcare Diagnostics, Erlangen, Germany), according to the manufacturer’s instructions. The lower limit
of detection of the cTnI assay was 0.04 mg?L-1. BNP levels were determined with an electrochemilumines-
cence immunoassay (BNP-Triage Biosite assay; Biosite Inc., San Diego, CA, USA) on a DxI analyser
(Beckman Coulter Inc., Brea, CA, USA). The lower limit of detection in the BNP assay was 10 ng?L- 1.
Outcomes
30-day clinical follow-up data were obtained for all patients. Adverse clinical events were defined as all-
cause death, secondary cardiogenic shock as previously defined, or objectively confirmed symptomatic
recurrent venous thromboembolism. All adverse events and the cause of death (i.e. related or unrelated to
PE) were adjudicated by an independent committee of two physicians unaware of the results of the initial
clinical examination, echocardiography and biomarker determinations.
The study was an academic trial sponsored by the De´le´gation a` la Recherche Clinique d’Ile de France. The
funding body had no role in the design of the study, data analysis, or drafting the manuscript. The study was
approved by local ethics committees (Ile de France II, Saint-Luc University Hospital and Geneva University
Hospital committees for the French, Belgian and Swiss centres, respectively). All patients signed a written
informed consent form.
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Statistical methods
Categorical variables were summarised using numbers and percentages, and continuous variables using
median (interquartile range). PESI score was categorised into low risk (PESI class I or II), intermediate risk
(PESI class III or IV) and high risk (PESI class V) categories. Proportions of deaths and adverse events
according to the PESI risk class were compared using Chi-squared tests; median values of markers according
to PESI risk class were compared using Kruskall–Wallis tests.
Univariate analyses, based on Chi-squared tests or t-tests, were performed. Independent associations with
the outcome were assessed by including variables with a significance level of p,0.20 on univariate analysis
in a multivariate logistic regression model. Variables associated with the outcome at a significance level of
p,0.05 in backward stepwise regression analysis were retained. For the multivariate analysis, we conducted
multiple imputation analysis to ensure that the results were robust for missing data. For each variable, we
further estimated the proportion of explained variation (PEV) and partial PEV. The PEV measures the
proportion of variation of the outcome variable that can be attributed to the variable, relative to the total
variation of the outcome variable. Partial PEV measures the decline in explained variation when removing
the prognostic factor from the model containing the other four factors.
In order to determine if echocardiography and biomarkers improved the risk stratification, we first
constructed box plots showing the distributions of biomarkers and echocardiography values within each
PESI risk class and among patients who did, or did not, experience an adverse event. In subsequent analyses,
echocardiography and biomarkers were dichotomised according to thresholds validated in previous studies.
We defined a BNP concentration .100 ng?L-1 as positive BNP [10, 11], a cTnI concentration .0.1 mg?L-1
as positive cTnI [10, 12] and a right ventricle/left ventricle ratio .0.9 as a positive right ventricle/left
ventricle ratio [10, 12]. We then cross-classified patients according to their PESI risk category and then
according to their right ventricle/left ventricle ratio or biomarker risk category, each in turn. Within each
sub-stratum, we estimated the risk of an adverse event. Finally, logistic regression analyses were conducted
to determine possible links between prognostic factors (PESI risk category, BNP, cTnI and right ventricle/
left ventricle end-diastolic diameter ratio) and the risk of an adverse event.
Results
Patients
A total of 592 consecutive patients were included in the study between January 2006 and May 2007. 41
patients were excluded because of cardiogenic shock at inclusion. 22 haemodynamically stable patients were
excluded because they were receiving fibrinolytic treatment. None of these normotensive patients
experienced a 30-day adverse event. The final study population, therefore, comprised 529 patients with
normotensive PE (table 1). At inclusion, 528 patients (99%) were receiving an anticoagulant treatment.
Fibrinolytic therapy was administered to eight patients (1.5%) because of secondary cardiogenic shock. A
vena cava filter was inserted in 22 patients (4%).
Outcome
The 30-day prospective follow-up was complete for all patients. During follow-up, 25 patients (4.7%, 95%
CI 3.2–6.9%) suffered adverse events: death in 15 cases (2.8%, 95% CI 1.7–4.6%), secondary cardiogenic
shock in 15 (2.8%) and recurrent venous thromboembolism in eight patients (1.5%). One patient may have
had several events qualifying for complicated outcome.
PESI
The PESI was calculated for all 529 patients; among them, 329 (62%) were at low risk (PESI class I or II),
179 patients (34%) were at intermediate risk (PESI class III or IV) and 21 patients (4%) were at high risk
(PESI class V). The mortality rate and the rate of adverse outcomes, including mortality, secondary
cardiogenic shock and recurrent PE, increased significantly from 0.6% and 2.1% in the low-risk category to
9.5% and 14.3% in the high-risk category, respectively (table 2).
Biomarkers and echocardiography
Plasma concentrations of BNP and cTnI, and the right ventricle/left ventricle ratio increased significantly
with the PESI (table 2).
Predictors of adverse outcome
Figure 1 shows the number and proportion of patients with an adverse outcome at 30 days in the six
categories defined by cross-tabulation of the PESI risk class (low, intermediate or high risk) and the right
ventricular dysfunction marker category (normal or elevated biomarkers; normal or abnormal right
ventricle/left ventricle ratio). All biomarkers and echocardiography results enabled patients belonging to the
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low-risk category (PESI class I or II), to be further stratified into two subgroups, one with a very low risk
(f1%) of an adverse outcome and one with a 6% risk of 30-day adverse outcome, with significant differences
in the event rate between the subgroups with normal and abnormal biomarker and right ventricle/left ventricle
ratio values (p50.03 for BNP; p,0.001 for cTnI and p,0.001 for right ventricle/left ventricle ratio) (fig. 1). In
the intermediate risk group of patients (PESI class III–IV), elevated biomarkers and right ventricular dilatation
on echocardiography were associated with higher rates of adverse outcomes, but the difference to patients
having normal values was significant for cTnI only (p50.02 for cTnI; p50.42 for BNP and p50.9 for
echocardiography) (fig. 1). In the high-risk group (PESI class V), differences in the event rates between
patients with normal and abnormal biomarker values and echocardiography were less pronounced and not
significant, but the patient population was small (fig. 1).
TABLE 1 Characteristics of the 529 patients with pulmonary embolism
Characteristics Available data All 30-day adverse event
Yes No
Patients 529 25 504
Age years 529 67 (52–77) 70 (60–81) 67 (51–77)
Male 529 247 (47) 12 (48) 235 (47)
Cancer 529 77 (15) 7 (28) 70 (14)
Altered mental state 529 7 (1) 1 (4) 6 (1)
Syncope 529 24 (5) 2 (8) 22 (4)
Heart rate beats?min-1 526 88 (75–100) 90 (80–103) 88 (74–100)
Systolic blood pressure mmHg 529 134 (120–150) 130 (124–140) 135 (120–150)
Cardiogenic shock on admission 529 0 (0) 0 (0) 0 (0)
PESI class 529
I (f65 points) 131 (25) 1 (4) 130 (26)
II (66–85 points) 198 (37) 6 (24) 192 (83)
III (86–105 points) 109 (21) 10 (40) 99 (20)
IV (106–125 points) 70 (13) 5 (20) 65 (13)
V (.125 points) 21 (4) 3 (12) 18 (4)
Echocardiography and cardiac biomarkers
BNP ng?L-1 521 71.0 (27.0–210.0) 275.0 (69.0–431.0) 67.0 (27.0–190.0)
Cardiac troponin I mg?L-1 517 0.01 (0.00–0.06) 0.11 (0.01–0.34) 0.01 (0.00–0.05)
Right ventricle/left ventricle EDD ratio 484 0.65 (0.53–0.79) 0.76 (0.63–1.11) 0.65 (0.53–0.79)
Data are presented as n, median (interquartile range) or n (%). PESI: pulmonary embolism severity index; BNP: brain natriuretic peptide; EDD: end-
diastolic diameter.
TABLE 2 Rate of adverse outcomes and value of biomarkers and echocardiography according to the pulmonary embolism
severity index (PESI) classes
PESI class p-value
I–II (low risk) III–IV (intermediate
risk)
V (high risk)
Patients 329 179 21
End-points
30-day mortality 2 (0.6) 11 (6.1) 2 (9.5) ,0.001
30-day adverse event 7 (2.1) 15 (8.4) 3 (14.3) ,0.001
Echocardiography and cardiac biomarkers
BNP ng?L-1 44.5 (21.5–146.0) 126.5 (46.0–299.0) 221.0 (130.0–385.0) ,0.001
Cardiac troponin I mg?L-1 0.01 (0.00–0.04) 0.01 (0.00–0.10) 0.03 (0.00–0.19) ,0.01
Right ventricle/left ventricle EDD ratio 0.63 (0.51–0.76) 0.71 (0.56–0.86) 0.59 (0.51–0.88) 0.02
Data are presented as n, n (%) or median (interquartile range), unless otherwise stated. Distributions of deaths and adverse events according to
PESI risk class were compared using Chi-squared tests; distributions of markers according to PESI risk class were compared using Kruskall–
Wallis tests. BNP: brain natriuretic peptide; EDD: end-diastolic diameter.
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Results of univariate logistic regression analyses showed that the PESI, BNP and right ventricle/left ventricle
ratio were significantly associated with the occurrence of an adverse outcome (table 3). Multivariate analysis
showed that, in addition to the PESI risk class, echocardiography but not biomarkers remained independent
predictors of adverse outcome at day 30 in the study population (table 4). The variables included in the
model accounted for about 10% of the variation in individual 30-day outcomes; the proportions of variance
explained by each right ventricular dysfunction marker (as well as partial PEV) were similar to those
explained by the PESI risk class. Finally, multiple imputation analysis provided estimates consistent with the
complete case analysis (table 4). The PESI was associated with a moderate prognostic sensitivity (72%) and
high negative predictive value (98%) (table 5). Interestingly, the combination of PESI with right ventricle/
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FIGURE 1 The figure shows the number and proportion of patients with an
adverse 30-day outcome in categories defined by cross-tabulation of
pulmonary embolism severity index (PESI) risk classes, and right
ventricular (RV) dysfunction defined by elevated cardiac biomarker levels
or RV/left ventricular (LV) ratio, according to previously validated
thresholds. Complete cases are presented. Data are presented as % (n)
and N, where N is the total number of patients. a) PESI class I–II, b) PESI
class III–IV and c) PESI class V. BNP: brain natriuretic peptide; cTnI:
cardiac troponin I. #: p50.03; ***: p,0.001; ": p50.02.
TABLE 3 Univariate analysis
Variable Complete cases n OR (95% CI) p-value
PESI class 529 ,0.01
III–IV versus I–II 4.2 (1.7–10.5)
V versus I–II 7.7 (1.8–32.1)
BNP# 521 1.3 (1.1–1.6) ,0.01
Cardiac troponin I" 517 1.2 (0.9–1.5) 0.20
Right ventricle/left ventricle EDD ratio+ 484 1.3 (1.2–1.5) ,0.0001
PESI: pulmonary embolism severity index; BNP: brain natriuretic peptide; EDD: end-diastolic diameter. #: for
an increase of 250 ng?L-1; ": for an increase of 0.7 mg?L-1; +: for an increase of 0.1.
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left ventricle ratio had a higher sensitivity and negative predictive value for predicting 30-day complicated
outcome (table 5).
Discussion
This study shows that in patients with normotensive PE, right ventricular dysfunction on echocardiography
provides prognostic information that is independent of clinical findings summarised by the PESI. In
patients considered at low-risk according to the PESI, echocardiography and biomarkers identified two
subgroups with different risks of adverse events. Among patients belonging to PESI class I or II, those with
normal echocardiography results and normal levels of biomarkers had a very low risk of adverse events,
which was significantly lower than the rate observed in patients with an abnormal echocardiography or
elevated levels of biomarkers.
Five groups of patients with different risks of death were described in the original report describing the
PESI. Subsequently, class I and II patients were combined in a low-risk group and were selected as possible
candidates for outpatient treatment [13] and patients in class III to V were considered as ‘‘high-risk’’
patients [5, 6]. In the present study, three groups were considered: one ‘‘low-risk’’ group corresponding to
the usual low-risk group (defined as PESI class I or II), an ‘‘intermediate-risk’’ group defined as PESI class
III or IV patients, and a ‘‘high-risk’’ group defined as PESI class V patients. This was done to comply with
the recommendations of the European Society of Cardiology, in which three groups are considered [2].
Clustering the high-risk and intermediate groups or using the simplified PESI did not change the results
(data not shown). Previous studies have compared the clinical approach based on the PESI and biomarkers
or echocardiography for the risk stratification of PE with varying results. The respective values of cTnI and
the original PESI for the prediction of mortality at 30 days were evaluated in a monocentric cohort of 567
patients with clinically stable PE [14]. In this study, the combination of cTnI with the clinical variables did
not improve the negative predictive value of the PESI for the risk of 30-day mortality, but the other major
adverse events, such as recurrent PE or cardiogenic shock, were not evaluated [14]. The prognostic value of
the new high sensitivity troponin T (hsTnT) assay and of the simplified PESI was evaluated in a multicentre
study including 526 normotensive patients with PE [15]. The hsTnT assay was associated with a high
prognostic sensitivity and negative predictive value comparable to those of the simplified PESI. hsTnT and
TABLE 4 Multivariate analysis
Variable Complete cases# Multiple imputation"
OR (95% CI) p-value PEV % Partial PEV % OR (95% CI) p-value
PESI class 0.03 0.02
III–IV versus I–II 3.1 (1.2–8.3) 1.5 0.0 3.4 (1.3–8.8)
V versus I–II 5.5 (1.2–25.5) 0.9 1.0 6.2 (1.3–28.2)
BNP+ 1.1 (0.8–1.4) 0.58 0.8 0.0 1.1 (0.8–1.5) 0.49
Cardiac troponin I1 1.3 (0.9–2.0) 0.23 0.2 0.3 1.1 (0.8–1.6) 0.45
Right ventricle/left ventricle EDD ratioe 1.3 (1.1–1.5) ,0.01 6.7 3.1 1.3 (1.1–1.5) ,0.01
Model 10.1
Missing values for any prognostic variable (heart rate n53, respiratory rate n571, temperature n54, arterial oxyhaemoglobin saturation n54) were
assumed to be normal, a strategy used in the original determination of the pulmonary embolism severity index (PESI) [3]. PEV: proportion of
explained variation, i.e. the amount of variation of the outcome variable that is attributable to the variable, relative to the total variation of the
outcome variable; partial PEV measures the decline in explained variation when removing the prognostic factor from the model containing all four
other factors; BNP: brain natriuretic peptide; EDD: end-diastolic diameter. #: n5473; ": n5529; +: for an increase of 250 ng?L-1; 1: for an increase of
0.7 mg?L-1; e: for an increase of 0.1.
TABLE 5 Value of pulmonary embolism severity index (PESI) alone and right ventricle/left ventricle (RV/LV) ratio alone and in
combination for predicting a 30-day complicated outcome
Sensitivity Specificity Positive predictive value Negative predictive value
PESI class III–IV–V 72 (18/25) 64 (294/459) 10 98
RV/LV .0.9 36 (9/25) 85 (389/459) 11 96
PESI class III–IV–V and RV/LV ratio .0.9 88 (22/25) 57 (261/459) 10 99
Data are presented as % (n/N) or %.
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the simplified PESI were identified as independent predictors of 30-day complicated outcome defined by
all-cause death or secondary shock or cardiopulmonary resuscitation [15]. Interestingly, the combination of
elevated hsTnT with high risk simplified PESI had a sensitivity and negative predictive value of 100% [15].
By contrast, none of the patients with low-risk simplified PESI and low levels of hsTnT experienced an
adverse outcome, but the authors did not report whether patients with low-risk simplified PESI and
elevated hsTnT had a higher rate of adverse outcomes [15]. Recently, the simplified PESI has been
compared to a risk-stratification method based on echocardiography and biomarkers proposed by recent
European Society of Cardiology recommendations [12]. The combined end-point of all-cause mortality,
objectively confirmed non-fatal symptomatic recurrent venous thromboembolism or non-fatal major
bleeding was lower in the low-risk group identified by the simplified PESI than in the low-risk group
identified by normal echocardiography findings and biomarker assays [12]. An approach combining clinical
findings, echocardiography and biomarkers was not tested in this study. In another monocentric study, it
was shown that right ventricular dysfunction and/or a high cTnI level increased the risk of death in patients
classified as intermediate risk according to the PESI, whereas this was not observed in low-risk patients [16].
The additional role of echocardiography and biomarkers in predicting other major complications was not
tested in this study.
Recently, AUJESKY et al. [13] demonstrated in an open-label multicentre randomised trial that outpatient
treatment is not inferior to inpatient care in terms of efficacy and safety in selected low-risk patients (PESI
class I or II). In this study, neither echocardiography nor biomarkers were used for the risk stratification,
but more than two-thirds of the patients included were in the very low risk PESI class I [13]. Our results
suggest that among patients belonging PESI class I or II, those with elevated levels of biomarkers or
abnormal echocardiography results could require hospitalisation instead of outpatient care. However, our
results must be confirmed in large independent cohort studies before being used to make a therapeutic
decision.
The present study has several strengths; it was multicentre, enabling greater generalisation of the results, and
patients were consecutively and prospectively recruited, limiting the possibility of major biases. All
outcomes were assessed by an independent central committee whose members were unaware of the initial
clinical data and results of echocardiography and biomarkers. The biomarkers were measured at the end of
the study and the responsible physicians were also unaware of the results of biomarker assays and these
results did not influence initial treatment. Conversely, participating physicians were aware of
echocardiography results and their initial treatment option, i.e. anticoagulation alone or anticoagulation
and thrombolysis may have been influenced by the results of echocardiography; this is why normotensive
patients who received thrombolytic treatment were excluded from the analysis. The study was also limited
by the low number of events and by the small number of patients in the intermediate and high-risk
categories. This may explain why the difference between the proportion of intermediate-risk patients with
outcome having abnormal echocardiography results or elevated biomarkers compared to those with normal
results, was not statistically significant.
In conclusion, if confirmed in independent cohort studies, the present findings suggest that cardiac
biomarkers and/or echocardiography will enable patients with a PESI I–II to be further stratified into two
subgroups, one with a very low level of adverse outcome that can be safely treated as outpatients and one
with a slightly higher risk requiring hospitalisation. The role of biomarkers and echocardiography in
patients at intermediate or high risk according to the PESI is more questionable and should be evaluated in
larger cohorts.
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